Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Hagene, K. T., Brunsvig, P., Yndestad, A., Halvorsen, B., Tasken, K. A., Aukrust, P., Mælandsmo, G. M., Ueland, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591141/
https://www.ncbi.nlm.nih.gov/pubmed/30821848
http://dx.doi.org/10.1111/cei.13283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591141/
https://www.ncbi.nlm.nih.gov/pubmed/30821848
http://dx.doi.org/10.1111/cei.13283

Ejemplares similares